RemeGen Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGMF research report →
Price Chart
About the company
RemeGen Co. , Ltd. , a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
- CEO
- Jian Min Fang
- IPO
- 2021
- Employees
- 3,048
- HQ
- Yantai, SD, CN
Get TickerSpark's AI analysis on REGMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $5.61B
- P/E
- 7.49
- Fwd P/E
- 1.17
- PEG
- 0.00
- P/S
- 5.89
- P/B
- 5.50
- EV/EBITDA
- 7.74
- Div Yield
- 0.00%
- Gross Margin
- 92.17%
- Op Margin
- 60.87%
- Net Margin
- 78.75%
- ROE
- 105.60%
- ROIC
- 54.41%
Latest fiscal year · YoY change
- Revenue
- $3.17B+85.2%
- Gross Profit
- $2.55B+86.5%
- Op Income
- $126.84M
- Net Income
- $690.24M+147.0%
- EPS
- $1.26+146.2%
- OCF Growth
- +104.7%
- FCF Growth
- +90.3%
- 52W High
- $12.85
- 52W Low
- $9.50
- 50D MA
- $10.06
- 200D MA
- $11.04
- Beta
- 0.45
- RSI (14)
- 23
- Avg Volume
- 47
No earnings-call transcripts are available for REGMF yet.
- Free Float
- 80.7%
- Shares Outstanding
- 563.61M
- Float Shares
- 454.61M
Our REGMF coverage
Recent articles, reports, and earnings notes.
No research on REGMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REGMF report →AbbVie, RemeGen partner on experimental solid tumor treatment
reuters.com · Jan 12
Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 45.0%
defenseworld.net · Dec 29
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
prnewswire.com · Aug 18
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
prnewswire.com · Aug 8
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
businesswire.com · Jun 26
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
prnewswire.com · Jun 17
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
prnewswire.com · May 27
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
prnewswire.com · Apr 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.